SIGA
SIGA Technologies, Inc.6.28
-0.04-0.63%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
449.72MP/E (TTM)
6.10Basic EPS (TTM)
1.03Dividend Yield
0%Recent Filings
10-K
FY2025 results
SIGA Technologies posted FY2025 revenues of $94.6 million, down from $138.7 million in FY2024, as product sales fell to $88.0 million—including $53.3 million oral TPOXX® and $25.8 million IV TPOXX® under the 19C BARDA Contract, plus $5.8 million international—while R&D contract revenue rose to $6.5 million. Q4 momentum slowed with international sales plunging 75% y/y to $5.8 million total, yet U.S. Government deliveries held steady amid BARDA options fully exercised at $545 million; margins held as costs dipped to $29.7 million. Cash stayed flat at $155 million after a $43 million special dividend. No new annual guidance disclosed. BARDA contract termination risk looms large.
8-K
SIGA's 2025 revenues drop
SIGA Technologies reported $88M in TPOXX product sales for 2025, down sharply from $133M in 2024, yielding $24M pre-tax operating income. Total revenues hit $95M with $24M operating income. Secured $13M Asia Pacific oral TPOXX order in January 2026 under multi-year contract; deliveries set for 2026. Revenue plunged yet pipeline endures.
8-K
SIGA Q3 loss, strong YTD sales
SIGA Technologies reported Q3 2025 results, posting a $10.2M operating loss after $86M nine-month product sales—down from Q3 2024's $8.9M quarterly sales but up year-to-date versus $53.5M. BARDA added $27M to TPOXX development; Japan approved TEPOXX in January. Cash sits at $172M. Government contracts drive revenues.
10-Q
Q3 FY2025 results
SIGA's Q3 revenues dropped 74% y/y to $2.6M from $10.0M, all over-time R&D under the 19C BARDA contract—no product sales this quarter—while YTD revenues soared 59% y/y to $90.8M (derived), fueled by $85.8M product sales including $79.1M point-in-time U.S. government deliveries. Operating loss hit $10.2M versus prior-year income, but YTD operating income jumped to $33.2M; net loss of $6.4M reflected higher self-funded R&D, while YTD net income reached $28.7M ($0.40 diluted EPS, reconciled). Cash swelled to $172M after $60.3M operating cash flow less $0.3M capex (FCF $60.0M, derived), despite $43M special dividend; no debt. Cash balances nicely. EMA probes Tecovirimat-SIGA efficacy for mpox.
IPO
Website
Employees
Sector
Industry
DVAX
Dynavax Technologies Corporatio
10.78-0.07
EBS
Emergent BioSolutions Inc.
12.19-0.14
HSTI
High Sierra Technologies Inc.
1.40+0.00
HYEX
HEALTHY EXTRACTS INC.
1.99-0.22
NIKA
NIKA PHARMACEUTICALS INC.
0.28+0.00
PTPI
Petros Pharmaceuticals, Inc.
0.01-0.00
RAPH
RAPHAEL PHARMACEUTICAL INC
1.40+0.00
SIGY
Sigyn Therapeutics Inc.
1.71-0.19
SNGX
Soligenix, Inc.
1.52-0.03
ZYBT
Zhengye Biotechnology Holding L
1.86-0.07